「by」の検索結果
76件：11～15件目を表示
-
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
orado, United States of America Motugivatrep suppresses the expression of proinflammatory mediators by inhibiting TRPV1 activation mediated by hyperosmotic and inflammatory stimuli in human corneal ep...
https://www.senju.co.jp/english/rd/society/ -
Meetings of the Minds | Research & Development | SENJU Pharmaceutica
orado, United States of America Motugivatrep suppresses the expression of proinflammatory mediators by inhibiting TRPV1 activation mediated by hyperosmotic and inflammatory stimuli in human corneal ep...
http://www.senju.co.jp/english/rd/society/ -
ical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of software for dry-eye analysis in Japan as an option of RE...
https://www.senju.co.jp/system/files/content_news/2024-09/ENG_20240906.pdf -
that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction by pharmacist, hereinafter this "Product") from Ministry of Health, Labour and Welfare. Th...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903_0.pdf -
that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction by pharmacist, hereinafter this "Product") from Ministry of Health, Labour and Welfare. Th...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903.pdf